HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Clinical trials for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER trials appear
Sign up with your email to follow new studies for HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for metastatic breast cancer: pill combo may replace chemo
Disease control OngoingThis pilot study tests two oral drugs, anastrozole and palbociclib, in postmenopausal women with a common type of metastatic breast cancer (HR+/HER2-). The drugs are given either as the first treatment or as maintenance after chemotherapy. The main goal is to see if the combinati…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising new combo for Hard-to-Treat breast cancer
Disease control OngoingThis phase 2 study tests the drug abemaciclib, either alone or with tamoxifen, in 234 women with a specific type of advanced breast cancer (HR+, HER2-). The goal is to see if these treatments can slow cancer growth in patients whose disease has progressed after prior therapies. P…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Can adding immunotherapy to standard drugs fight resistant breast cancer?
Disease control OngoingThis phase 2 trial tests three drug combinations—fulvestrant alone, fulvestrant plus palbociclib, and fulvestrant plus palbociclib plus avelumab—in 220 people with ER+/HER2- metastatic breast cancer that has progressed after prior CDK inhibitor therapy. The goal is to see which c…
Matched conditions: HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC